Cytotoxic agents in sarcoidosis: which one should we choose?
Identifieur interne : 000287 ( PubMed/Curation ); précédent : 000286; suivant : 000288Cytotoxic agents in sarcoidosis: which one should we choose?
Auteurs : Adriane D M. Vorselaars ; Johanna P. Cremers ; Jan C. Grutters ; Marjolein DrentSource :
- Current opinion in pulmonary medicine [ 1531-6971 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- traitement médicamenteux : Sarcoïdose.
- usage thérapeutique : Cytotoxines, Immunosuppresseurs.
- Humains.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Cytotoxins, Immunosuppressive Agents.
- drug therapy : Sarcoidosis.
- Humans.
Abstract
Sarcoidosis is a granulomatous disease which affects multiple organs. Its therapeutic management is very challenging due to the heterogeneity in disease manifestation and clinical course, as well as the potential side effects of the immunosuppressive therapy. An overview of presently available second-line and third-line systemic agents is provided.
DOI: 10.1097/MCP.0000000000000078
PubMed: 25046427
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000287
Links to Exploration step
pubmed:25046427Curation
No country items
Adriane D M. Vorselaars<affiliation><nlm:affiliation>aCentre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, Nieuwegein bild care expertise team, Department of Respiratory Medicine, Hospital Gelderse Vallei, Ede cDepartment of Internal Medicine, Atrium Medical Centre, Heerlen dDivision of Heart and Lungs, University Medical Centre Utrecht, Utrecht eDepartment of Toxicology, Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands *Adriane D.M. Vorselaars and Johanna P. Cremers contributed equally to the writing of this article.</nlm:affiliation><wicri:noCountry code="subField">The Netherlands *Adriane D.M.</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cytotoxic agents in sarcoidosis: which one should we choose?</title><author><name sortKey="Vorselaars, Adriane D M" sort="Vorselaars, Adriane D M" uniqKey="Vorselaars A" first="Adriane D M" last="Vorselaars">Adriane D M. Vorselaars</name><affiliation><nlm:affiliation>aCentre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, Nieuwegein bild care expertise team, Department of Respiratory Medicine, Hospital Gelderse Vallei, Ede cDepartment of Internal Medicine, Atrium Medical Centre, Heerlen dDivision of Heart and Lungs, University Medical Centre Utrecht, Utrecht eDepartment of Toxicology, Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands *Adriane D.M. Vorselaars and Johanna P. Cremers contributed equally to the writing of this article.</nlm:affiliation><wicri:noCountry code="subField">The Netherlands *Adriane D.M.</wicri:noCountry></affiliation></author><author><name sortKey="Cremers, Johanna P" sort="Cremers, Johanna P" uniqKey="Cremers J" first="Johanna P" last="Cremers">Johanna P. Cremers</name></author><author><name sortKey="Grutters, Jan C" sort="Grutters, Jan C" uniqKey="Grutters J" first="Jan C" last="Grutters">Jan C. Grutters</name></author><author><name sortKey="Drent, Marjolein" sort="Drent, Marjolein" uniqKey="Drent M" first="Marjolein" last="Drent">Marjolein Drent</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25046427</idno><idno type="pmid">25046427</idno><idno type="doi">10.1097/MCP.0000000000000078</idno><idno type="wicri:Area/PubMed/Corpus">000287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000287</idno><idno type="wicri:Area/PubMed/Curation">000287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000287</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cytotoxic agents in sarcoidosis: which one should we choose?</title><author><name sortKey="Vorselaars, Adriane D M" sort="Vorselaars, Adriane D M" uniqKey="Vorselaars A" first="Adriane D M" last="Vorselaars">Adriane D M. Vorselaars</name><affiliation><nlm:affiliation>aCentre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, Nieuwegein bild care expertise team, Department of Respiratory Medicine, Hospital Gelderse Vallei, Ede cDepartment of Internal Medicine, Atrium Medical Centre, Heerlen dDivision of Heart and Lungs, University Medical Centre Utrecht, Utrecht eDepartment of Toxicology, Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands *Adriane D.M. Vorselaars and Johanna P. Cremers contributed equally to the writing of this article.</nlm:affiliation><wicri:noCountry code="subField">The Netherlands *Adriane D.M.</wicri:noCountry></affiliation></author><author><name sortKey="Cremers, Johanna P" sort="Cremers, Johanna P" uniqKey="Cremers J" first="Johanna P" last="Cremers">Johanna P. Cremers</name></author><author><name sortKey="Grutters, Jan C" sort="Grutters, Jan C" uniqKey="Grutters J" first="Jan C" last="Grutters">Jan C. Grutters</name></author><author><name sortKey="Drent, Marjolein" sort="Drent, Marjolein" uniqKey="Drent M" first="Marjolein" last="Drent">Marjolein Drent</name></author></analytic><series><title level="j">Current opinion in pulmonary medicine</title><idno type="eISSN">1531-6971</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cytotoxins (therapeutic use)</term><term>Humans</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Sarcoidosis (drug therapy)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Cytotoxines (usage thérapeutique)</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Humains</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Sarcoïdose (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cytotoxins</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sarcoïdose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cytotoxines</term><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sarcoidosis is a granulomatous disease which affects multiple organs. Its therapeutic management is very challenging due to the heterogeneity in disease manifestation and clinical course, as well as the potential side effects of the immunosuppressive therapy. An overview of presently available second-line and third-line systemic agents is provided.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25046427</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-6971</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Current opinion in pulmonary medicine</Title><ISOAbbreviation>Curr Opin Pulm Med</ISOAbbreviation></Journal><ArticleTitle>Cytotoxic agents in sarcoidosis: which one should we choose?</ArticleTitle><Pagination><MedlinePgn>479-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MCP.0000000000000078</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Sarcoidosis is a granulomatous disease which affects multiple organs. Its therapeutic management is very challenging due to the heterogeneity in disease manifestation and clinical course, as well as the potential side effects of the immunosuppressive therapy. An overview of presently available second-line and third-line systemic agents is provided.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Because curative treatment is currently not available for sarcoidosis, nonspecific immunosuppression with prednisone remains the first-choice therapy. However, as chronic use of corticosteroids is accompanied with severe adverse events, timely implementation of appropriate steroid-sparing cytotoxic agents is important. Commonly prescribed second-line agents in sarcoidosis are methotrexate, azathioprine, leflunomide and hydroxychloroquine. Nevertheless, the evidence supporting their use is limited. Third-line treatment options, including tumor necrosis factor-alpha inhibitors infliximab and adalimumab and the experimental therapeutic rituximab, are currently reserved for patients refractory to standard therapy.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">A better insight into the advantages and disadvantages of second-line and third-line treatment is important. The long-term effects of immunosuppressive agents, the optimal starting and maintenance dosages, and the best interval and discontinuation regimens should be elucidated. Identified associations of polymorphisms with treatment response suggest a step towards personalized medicine. Future research should focus on the role for pharmacogenetic and phenotypic predictors of treatment response and toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vorselaars</LastName><ForeName>Adriane D M</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>aCentre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, Nieuwegein bild care expertise team, Department of Respiratory Medicine, Hospital Gelderse Vallei, Ede cDepartment of Internal Medicine, Atrium Medical Centre, Heerlen dDivision of Heart and Lungs, University Medical Centre Utrecht, Utrecht eDepartment of Toxicology, Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands *Adriane D.M. Vorselaars and Johanna P. Cremers contributed equally to the writing of this article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cremers</LastName><ForeName>Johanna P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Grutters</LastName><ForeName>Jan C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Drent</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Pulm Med</MedlineTA><NlmUniqueID>9503765</NlmUniqueID><ISSNLinking>1070-5287</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003603">Cytotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439524">TNF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003603" MajorTopicYN="N">Cytotoxins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25046427</ArticleId><ArticleId IdType="doi">10.1097/MCP.0000000000000078</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000287 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000287 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25046427
|texte= Cytotoxic agents in sarcoidosis: which one should we choose?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25046427" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |